The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books
Feb 21, 2019 • 24min
Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill
Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering scheme. Then Dr. Laura Esserman of the University of California, San Francisco, comes on to break down the debate over genetic testing for cancer risk. And then we give you the need-to-know on an upcoming Senate hearing that will see seven pharma executives get grilled on the rising cost of medicines in the U.S.
Feb 14, 2019 • 24min
Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH
When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?
Feb 7, 2019 • 26min
Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from?
Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?
Jan 31, 2019 • 25min
Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns
Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?
Jan 24, 2019 • 25min
Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics
Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?
Jan 17, 2019 • 24min
Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics
Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?
Jan 10, 2019 • 15min
Episode 43: A people's history of J.P. Morgan
Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?
Jan 3, 2019 • 22min
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring
Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?
Dec 20, 2018 • 27min
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta
What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?
Dec 13, 2018 • 23min
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests
Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?
